Imugene (ASX:IMU) Other Current Liabilities: A$3.17 Mil (As of Dec. 2025)


ASX:IMU Imugene Ltd ASX:IMU
30 GF Score
Price A$0.14
! 4 Warning Signs
View Full Analysis

What is Imugene Other Current Liabilities?

Imugene ASX:IMU 30 Other Current Liabilities is A$3.17 Mil as of Dec. 2025. GuruFocus rates ASX:IMU with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Imugene's other current liabilities for the quarter that ended in Dec. 2025 was A$3.17 Mil.

Imugene's quarterly other current liabilities declined from Dec. 2024 (A$9.45 Mil) to Jun. 2025 (A$2.62 Mil) but then increased from Jun. 2025 (A$2.62 Mil) to Dec. 2025 (A$3.17 Mil).

Imugene's annual other current liabilities increased from Jun. 2023 (A$2.40 Mil) to Jun. 2024 (A$21.49 Mil) but then declined from Jun. 2024 (A$21.49 Mil) to Jun. 2025 (A$2.62 Mil).

Imugene Other Current Liabilities Related Terms

Imugene Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Imugene's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imugene Other Current Liabilities Chart

Imugene Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.09 1.86 2.40 21.49 2.62

Imugene Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.50 21.49 9.45 2.62 3.17
ASX:IMU
30GF Score
Imugene Ltd ASX:IMU
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imugene Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of A$3.17 Mil mean?
Imugene (ASX:IMU) has a Other Current Liabilities of A$3.17 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Imugene.
Is Imugene's Other Current Liabilities too high?
Imugene's current Other Current Liabilities is A$3.17 Mil. Overall, Imugene has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Imugene's Other Current Liabilities compare to VRTX and REGN?
Imugene's Other Current Liabilities of A$3.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Imugene. Imugene's current Other Current Liabilities is A$3.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imugene stock overvalued right now?
Imugene (ASX:IMU) has a current Other Current Liabilities of A$3.17 Mil. The current Other Current Liabilities is A$3.17 Mil. Imugene's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Imugene (ASX:IMU), the current Other Current Liabilities is A$3.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imugene Business Description

Other Exchanges IUGNF:USAILA:Germany
Address 4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
30GF Score

Get the complete analysis for ASX:IMU

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price